ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the con...

Full description

Bibliographic Details

Published in:	Annals of oncology Vol. 33; no. 5; p. 466
Main Authors:	Passaro, A, Leighl, N, Blackhall, F, Popat, S, Kerr, K, Ahn, M J, Arcila, M E, Arrieta, O, Planchard, D, de Marinis, F, Dingemans, A M, Dziadziuszko, R, Faivre-Finn, C, Feldman, J, Felip, E, Curigliano, G, Herbst, R, Jänne, P A, John, T, Mitsudomi, T, Mok, T, Normanno, N, Paz-Ares, L, Ramalingam, S, Sequist, L, Vansteenkiste, J, Wistuba, I I, Wolf, J, Wu, Y L, Yang, S R, Yang, J C H, Yatabe, Y, Pentheroudakis, G, Peters, S
Format:	Journal Article
Language:	English
Published:	England 01.05.2022
Subjects:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Consensus ErbB Receptors - genetics Humans Lung Neoplasms - genetics Lung Neoplasms - therapy Medical Oncology consensus lung cancer targeted therapy treatment EGFR testing
ISSN:	1569-8041, 1569-8041
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!